Anúncio
Anúncio
PTGX
Protagonist Therapeutics, Inc
87.21
USDPatrocinado
-0.13
-0.15%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
85.20
-2.01
-2.31%
Relatórios de Lucros PTGX
Rácio de surpresa positiva
PTGX separação 23 de 38 últimas estimativas.
61%
Próximo Relatório
Data do Próximo Relatório
19 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$9.10M
/-$0.61
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+93.22%
/-1.61%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-94.66%
/-130.81%
Protagonist Therapeutics, Inc earnings per share and revenue
On 06 de nov. de 2025, PTGX reported earnings of -0.62 USD per share (EPS) for Q3 25, beating the estimate of -0.65 USD, resulting in a 4.88% surprise. Revenue reached 4.71 milhão, compared to an expected 3.71 milhão, with a 27.04% difference. The market reacted with a -0.30% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of -0.61 USD, with revenue projected to reach 9.10 milhão USD, implying an diminuir of -1.61% EPS, and aumentar of 93.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Protagonist Therapeutics, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Protagonist Therapeutics, Inc reported EPS of -$0.62, beating estimates by 4.88%, and revenue of $4.71M, 27.04% above expectations.
How did the market react to Protagonist Therapeutics, Inc's Q3 2025 earnings?
The stock price moved down -0.3%, changed from $79.78 before the earnings release to $79.54 the day after.
When is Protagonist Therapeutics, Inc expected to report next?
The next earning report is scheduled for 19 de fev. de 2026.
What are the forecasts for Protagonist Therapeutics, Inc's next earnings report?
Based on 15
analistas, Protagonist Therapeutics, Inc is expected to report EPS of -$0.61 and revenue of $9.10M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio